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Background. Regulatory T cells (Tregs) suppress T-cell immune activation and human immunodeficiency virus type 1 (HIV-1) 
replication, but the role of Tregs in HIV-1 reservoir persistence is poorly defined.
Methods. Tregs were depleted by denileukin diftitox in humanized mice with chronic HIV-1 infection. Viral replication in 
lineage cells was determined by p24 expression. Levels of HIV-1 RNA and DNA in human cells, as well as replication-competent-vi-
rus–producing cells, were measured to quantified viral replication and reservoirs.
Results. Treg depletion resulted in a blip of HIV-1 replication in T cells but not in myeloid cells. The major activated res-
ervoir cells were memory CD4+ T cells in vivo. Interestingly, the transient activation of viral replication led to HIV-1 reservoir 
reduction after viremia resuppression, as indicated by the quantity of HIV-1 DNA and replication-competent-virus–producing cells. 
Furthermore, we demonstrated that Tregs use cyclic adenosine monophosphate (cAMP)–dependent protein kinase A pathway to 
inhibit HIV-1 activation and replication in resting conventional T cells in vitro.
Conclusion. Tregs suppress HIV-1 replication in T cells and contribute to HIV-1 reservoir persistence. cAMP produced in Tregs 
is involved in their suppression of viral gene activation and expression. Treg depletion combined with combination antiretroviral 
therapy provides a novel strategy for HIV-1 cure.
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Human immunodeficiency virus type 1 (HIV-1) reservoirs, 
which harbor replication competent proviruses and persist 
during combination antiretroviral therapy (cART), compose 
one of the major barriers to curing HIV-1 infection [1–3]. 
Activation of the latent and/or low-replicating reservoir and 
subsequent killing of HIV-infected cells is required for cure [4, 
5]. Studies suggest that pharmacological reagents such as his-
tone deacetylase inhibitors can activate latent HIV-1 infection 
[6, 7]. However, these reagents alone are unlikely to efficiently 
activate and eliminate HIV-1 reservoirs in vivo. New approaches 
are needed to efficiently reactivate and kill HIV-1 reservoirs [8].
Humanized mice, which are created by transplantation 
of human hematopoietic stem cells or lymphoid tissue in 
immune-deficient mice, have been used to study human in-
fectious diseases [9–11]. We have reported that NOD-rag1-/-
Il2rgnull (NRG) humanized (hu-NRG) mice with functional 
human immune cells support persistent HIV-1 infection during 
suppressive cART [12]. Therefore, the hu-NRG mouse is a vali-
dated small-animal model for studying HIV-1 infection, immu-
nopathogenesis, and therapy in vivo.
Regulatory T cells (Tregs) suppress T-cell activation and HIV-1 
replication but are susceptible to HIV-1 infection [13–15]. In early 
infection, Tregs help establish viral infection in the acute phase 
of infection via Vpr-dependent mechanisms [14, 16]. In chronic 
infection, Tregs suppress hyperimmune activation, which may 
favor HIV-1 reservoir persistence [13]. Study demonstrated that 
Tregs inhibit HIV-1 replication in activated CD4+ T cells via a cy-
clic adenosine monophosphate (cAMP)–dependent mechanism 
[17], suggesting that Tregs may contribute to HIV-1 latency or 
low replication in T cells. The precise role of Tregs in HIV-1 rep-
lication during chronic infection, as well as in cART-resistant res-
ervoirs, remains unknown. Here, we defined the role of Tregs in 
viral replication during chronic HIV-1 infection and its reactiv-
ation during cART in hu-NRG mice in vivo. Characterization of 
Treg-mediated suppression of HIV-1 replication and its reactiv-
ation during cART will shed light on the development of unique 
therapeutic approaches to cure HIV-1 infection.
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MATERIALS AND METHODS
Construction of Humanized Mice
Human fetal liver tissue specimens were obtained from elective 
or medically indicated termination of pregnancy through a non-
profit intermediary working with outpatient clinics (Advanced 
Bioscience Resources). Approval for animal work was obtained 
from University of North Carolina (UNC) Institutional Animal 
Care and Use Committee. We constructed hu-NRG mice as pre-
viously reported [14, 15, 18–20].
Virus Production and Infection
HIV-1JR-CSF or vesicular stomatitis virus G protein (VSV-G)–
pseudotyped HIV-1 expressing enhanced green fluorescent 
protein (EGFP) in nef were generated by transfection of pYK-
JRCSF or R7GEmC/VSV-G plasmids, respectively, in 293T 
cells, using the calcium phosphate method. All plasmids were 
obtained from the National Institutes of Health (NIH) AIDS 
Reagent Program. Virus titers were measured by a p24 enzyme-
linked immunosorbent assay (Cell Biolabs) and a MAGI-CCR5 
assay [21, 22]. Animals were infected with HIV-1JR-CSF at a dose 
of 10 ng of p24 per mouse, through retro-orbital injection.
cART Regimens
Protease inhibitor (Brecanavir; 100  mg/kg) [23, 24], reverse 
transcriptase inhibitor (GW695634 [clinical trials identi-
fier NCT00090077]; 100  mg/kg), and integrase inhibitor 
(Cabotegravir; 0.5 mg/kg) [25] were tested, formulated, and offered 
by GlaxoSmithKline as a preclinical test. All drugs were formulated 
as a wet-bead-milled suspension (2% Tween20, 2% PEG3350, and 
4.5% mannitol) and administered subcutaneously every 5 days.
Denileukin Diftitox
Denileukin diftitox (Ontak; 150  μg/mL in citrate buffer) was 
provided by Ligand Pharmaceuticals. Humanized mice were 
injected intraperitoneally (100 μg/kg) with denileukin diftitox 
for 3 consecutive days. The percentage of CD25high CD4+ T cells 
in blood was used to assess Treg depletion over time in vivo.
Plasma Viral Load
HIV-1 RNA was purified from plasma, using the QIAamp Viral 
RNA Mini Kit. RNA was reverse transcribed and quantitatively 
detected by real-time polymerase chain reaction (PCR) analy-
sis, using the TaqMan Fast Virus 1-Step PCR kit (ThermoFisher 
Scientific) and the QuantStudio 6 Flex PCR system (Applied 
Biosystems; detection limit, approximately 400 copies/mL) [12].
Flow Cytometry
Leukocytes were isolated from mouse lymphoid organs. 
Cells were stained and analyzed with either the CyAn ADP 
flow cytometer, using Summit 4.3 software (Dako), or a BD 
LSR Fortessa flow cytometer, using FACSDiva software (BD 
Biosciences). Data analysis was performed using Summit 4.3 or 
FlowJo software (FlowJo).
Cells were first stained with different combination of surface 
antibodies containing cell viability dye (anti-human HLA-DR-
FITC, CD38-PE, CD4-PE/Cy5, CD3-PE/Cy7, CD3-Pacific Blue, 
CD8-PE/Cy7, CD25-PE, CD127-PerCP/Cy5.5, CD14-Pacific 
Blue, CD123-APC, CD11c-PE, and CD45-APC/Cy7 [all from 
Biolegend]; and anti-mouse CD45-Pacific Orange, anti-hu-
man CD4-PE/Texas Red or CD8-PE/Texas Red, and Live/Dead 
Fixable Aqua Dead Cell Stain Kit [all from Invitrogen]) and 
then stained intracellularly with anti-HIV p24-FITC (Beckman 
Coulter) or anti-human Foxp3 eFluor 660 (Affymetrix eBiosci-
ence) according to the manufactures’ instructions, as previously 
described [12, 14, 18, 20].
Immunofluorescence Staining
Antigen was retrieved in Diva Decloaker solution (Biocare 
Medical) for 30 minutes at 95°C, followed by cooling down for 
1 hour. Tissue sections were blocked with Background Sniper 
(Biocare Medical), stained with the primary antibodies rabbit 
anti-human CD3 (Life Span Bio Sciences; 1:100 dilution) and 
mouse anti-HIV-1 p24 (Dako, 1:5 dilution) diluted in blocking 
buffer phosphate-buffered saline, 0.05% Tween 20, and 5% goat 
serum) overnight, and stained with the secondary antibodies 
Alexa Fluor 594 donkey anti-mouse immunoglobulin G (IgG; 
Life Technologies; 1:200 dilution) and Alexa Fluor 488 donkey 
anti-rabbit IgG (Life Technologies, 1:200 dilution). Finally, after 
DAPI staining, sections were mounted with antifade mounting 
medium (Abcam, Cambridge, MA). Sections were analyzed by 
confocal microscopy (Zeiss LSM 700).
Cell-Associated HIV-1 DNA
Total nucleic acid was extracted from spleen and bone marrow 
cells, using the DNeasy Mini Kit (Qiagen). HIV-1 DNA was quan-
tified by real-time PCR analysis. Genomic DNA of ACH2, which 
contains 1 copy of HIV-1 genome in each cell, was serially diluted 
in mouse leukocyte DNA to generate a standard curve [12].
Cell-Associated HIV-1 RNA
Total RNA was extracted from spleen or bone marrow cells, 
using the RNeasy Plus Mini Kit (Qiagen). HIV-1 RNA was 
detected as described above. HIV-1 gag RNA expression were 
normalized to that of human CD4 messenger RNA, and relative 
levels of HIV-1 gene expression were calculated according to 
the 2-ΔΔCT method [12, 26].
Viral Outgrowth Assay
Splenocytes from humanized mice (1 × 106, 2 × 105, and 4 × 104 
human cells in single, duplicates, or triplicates) were stimulated 
with phytohemagglutinin (2  μg/mL) and interleukin 2 (IL-2; 
100 units/mL) for 24 hours. MOLT4/CCR5 cells were added 
on day 2 to enhance the survival of leukocytes and to support 
HIV-1 replication. Culture medium containing IL-2 and T-cell 
growth factor [12] was replaced on days 5 and 9. After 7 and 
14 days of culture, supernatant was harvested individually, and 
HIV-1 real-time quantitative PCR was performed to score viral 
outgrowth. Estimated frequencies of cells with replication-com-
petent HIV-1 were calculated using limiting dilution analysis.
Cell Isolation and Culture
Peripheral blood mononuclear cells were isolated from human 
blood buffy coats (Gulf Coast Regional Blood Center), using 
Ficoll (GE Healthcare). Resting CD4+ T cells were purified 
first by use of the CD4+ T Cell Isolation Kit (Miltenyi Biotec) 
and subsequently by negative selection for CD25− cells, using 
CD25 beads. CD4+CD25+CD127dim/− Tregs were purified by the 
Regulatory T Cell Isolation Kit II (Miltenyi Biotec). All isola-
tion was done according to the manufacturer’s instructions. The 
purity of both conventional CD4+ T cells and Tregs was >90%.
In Vitro Culture Assay
Tregs or CD4+ T cells were first cultured with anti-CD3/CD28 
antibodies (2 µg/mL) for 24 hours and then washed thoroughly 
before coculture. All cell cultures were incubated at 37°C and 5% 
CO2 in the presence of 20 U/mL IL-2 in Roswell Park Memorial 
Institute 1640 medium supplemented with 100 U/mL penicil-
lin, 10 µg/mL streptomycin, 2 mM glutamine, 10 mM HEPES, 
and 10% fetal calf serum.
HIV-1-EGFP–transduced CD4+ T cells were cultured for 24 
hours and then subjected to the following assays. Cells were 
treated with the cAMP agonist Sp-8-Br-CAMPS (125 µM; 
Biolog Life Science Institute), protein kinase A (PKA) inhibi-
tor H89 (10 µM; Tocris Bioscience), or dimethyl sulfoxide indi-
vidually. Forty-eight hours later, 50% of the supernatant was 
replaced with fresh medium containing the same amount of 
each compound, and culturing continued for another 48 hours 
before analysis.
HIV-1-EGFP–transduced CD4+ T cells were cocultured with 
activated Tregs or CD4+ T cells at ratio of 2:1 or were treated 
with the cAMP antagonist Rp-8-Br-CAMPS (500 µM; Biolog 
Life Science Institute) for 48 hours, and 50% of the supernatant 
was replaced with fresh medium. In some assay, Tregs were pre-
viously treated with 2′,5′-dideoxyadenosine (ddADA; 200 µM; 
Sigma-Aldrich), an inhibitor of adenyl cyclase, for 24 hours 
before coculture. For the cAMP antagonist assay, the same 
amount of drug was complemented in fresh medium. All cells 
were cultured for another 48 hours before analysis. All medium 
contained 20 U/mL human IL-2.
Statistical Analysis
A paired 2-tailed Student t test was used for analysis of all in 
vitro assay data. A P value of < .05 was considered statistically 
significant. An unpaired t test or Mann-Whitney test was per-
formed to analyze animal data; a P value of < .05 was considered 
statistically significant. Data were analyzed using GraphPad 
Prism software, version 6.0 [15]. All data are reported as mean 
values ± standard deviations.
RESULTS
Persistent HIV-1 Infection and cART-Resistant Reservoirs in hu-NRG Mice
Blood samples were collected from the tail vein of hu-NRG mice 
infected with HIV-1JR-CSF for plasma viral load detection. HIV-1 
viremia persisted stably for >18 weeks after infection (Figure 1A 
and Supplementary Figure 1A). The CD4+ T-cell count decreased 
progressively over time (Supplementary Figure 1B–E), whereas 
CD8+ T cells showed a persistently higher level of immune acti-
vation in infected animals (Supplementary Figure 1F and 1G). 
To model HIV-1 therapy, we administered cART regimens to 
hu-NRG mice to stably suppress viral replication, as quantified 
either by the viremia level or by immunohistochemical stain-
ing of lymphoid tissues. cART was started 4 weeks after infec-
tion, when chronic infection had been established. As shown 
in Figure  1A, viremia became undetectable  2–3 weeks after 
cART initiation and remained undetectable during cART. We 
euthanized several animals 14 weeks after infection but before 
cART withdrawal, when viral replication was significantly sup-
pressed in cells (Figure 1B). Similar to findings in cART recip-
ients with undetectable viremia [27], cell-associated viral DNA 
could be frequently detected in spleens (Figure 1C), while rep-
lication-competent HIV-1 reservoirs remained (Figure 1D) in 
animals despite their abolished viremia and markedly reduced 
cell-associated viral RNA load as compared to cART-naive ani-
mals. In addition, HIV-1 replication rebounded rapidly upon 
cART cessation (Figure 1A and 1B) [28–31]. Therefore, HIV-1 
infection in hu-NRG mice is a relevant and robust model for 
studying persistent HIV-1 infection, immunopathogenesis, and 
cART-resistant reservoirs in vivo.
Tregs Suppress Viral Replication During Chronic HIV-1 Infection In Vivo
To confirm that denileukin diftitox, an IL-2 receptor binding 
domain fused to diphtheria toxin, could specifically deplete 
Tregs, we analyzed the frequency of Tregs or CD25+ T cells after 
denileukin diftitox treatment. We found that denileukin difti-
tox specifically depleted CD4+CD127−CD25highFoxP3+ Tregs 
(Supplementary Figure 2A and 2B) but not CD4+CD127+CD25+ 
(Supplementary Figure  2C and 2D) or CD4+CD127+FoxP3+ 
(Supplementary Figure 2E and 2F) T cells in lymphoid organs. 
CD8+CD25+ T cells were not significantly affected by denileukin 
diftitox in hu-NRG mice (Supplementary Figure 2G and 2H).
To determine the role of Tregs in chronic HIV-1 infection, 
we treated HIV-1–infected animals with denileukin diftitox 11 
weeks after infection with single injections on 3 consecutive 
days, and all animals were euthanized 13 weeks after infection. 
As expected, denileukin diftitox increased the frequency of 
HLA-DR+CD38+CD8+ T cells in hu-NRG mice (Supplementary 
Figure 3) [14, 15] and significantly increased the plasma viral 
load 2 weeks after denileukin diftitox treatment (Figure 2A). 
At the time mice were euthanized, HIV-1 gag p24 expression 
in CD4+ T cells in peripheral blood specimens, mesenteric 
lymphoid nodes, and spleen specimens was mostly expressed 
in CD3+CD8−CD4+ T cells (Figure 2B), and viral replication 
was significantly enhanced by denileukin diftitox (Figure 2C), 
which was confirmed by p24 immunohistochemical staining 
of spleen specimens (Figure 2D). These data suggest that Tregs 
suppress host immune activation and HIV-1 replication during 
chronic HIV-1 infection.
Treg Depletion Induces HIV-1 Activation During Suppressive cART in 
hu-NRG Mice
We hypothesized that Tregs contribute to the establishment 
and/or persistence of HIV-1 reservoirs during cART because of 
their suppression of T-cell activation and viral replication. To 
investigate the role of Tregs in HIV-1 reservoir maintenance, 
we started to deplete Tregs when viremia was completely sup-
pressed by cART (Figure 3A). Interestingly, Treg depletion in-
duced a blip of HIV-1 replication accompanied by a significant 
increase in the levels of cell-associated RNA in the spleen and 
bone marrow 12 weeks after infection (Figure 3A and 3B and 
Supplementary Figure 4). Immunohistochemical staining con-
firmed that a significant number of cells became p24 positive 
in the spleens of denileukin diftitox–treated mice, indicating 
that activation of HIV-1 replication was mediated by denileu-
kin diftitox treatment (Figure 3C). However, there was no sig-
nificant change in cell-associated viral DNA levels in lymphoid 
tissues 12 weeks after infection in denileukin diftitox–treated 
mice, compared with mice that received cART only (Figure 3D), 
nor was the level of cells with replication-competent virus 
affected by denileukin diftitox treatment (Supplementary 
Figure 5). The lack of increase in the number of HIV-1–infected 
cells indicates that the elevated HIV-1 replication induced by 
Treg depletion was not due to HIV-1 infection of new cells or 
to cART failure. We analyzed HIV-1 pol gene sequences from 
viruses associated with the rebound in viral load and found no 
mutations associated with cART resistance (data not shown), 
indicating that cART-resistant mutants or newly infecting virus 
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Figure 1. Humanized mice support persistent human immunodeficiency virus type 1 (HIV-1) infection and respond to combination antiretroviral therapy (cART) with cART-re-
sistant HIV-1 reservoirs. Humanized mice were infected with HIV-1JRCSF and started cART 4 weeks after infection. cART was stopped 14 weeks after infection (6 underwent 
mock infection [mock], 8 underwent HIV-1JRCSF infection and received phosphate-buffered saline [PBS] placebo [JRCSF+PBS], and 8 underwent HIV-1JRCSF infection and 
received cART [JRCSF+cART]). Several animals (3 in the mock group, 4 in the JRCSF+placebo group, and 4 in the JRCSF+cART group) were euthanized 14 weeks after infec-
tion. A, Plasma viral load measured over time. The dotted line indicates the detection limit (400 copies/mL), and “0” on the y-axis indicates that virus was undetected. B, 
Relative levels of cell-associated HIV-1 RNA in human cells from spleens were quantified by real-time polymerase chain reaction (PCR). C, Cell-associated HIV-1 DNA copies 
per million human cells in spleen, quantified by real-time PCR. D, Splenic cells producing replication-competent virus were detected by the quantitative virus outgrowth assay. 
Experiments were repeated twice. Data from each experiment were pooled and summarized. Error bars display standard deviations. *P < .05.
is not responsible for the viral load rebound. Thus, these results 
suggest that HIV-1 replication was reactivated from the cellular 
reservoir (harboring latent or low-level-replicating virus) by 
Treg depletion.
HIV-1 Is Reactivated From Memory CD4+ T Cells but Not Myeloid Cells 
Upon Treg Depletion
We used flow cytometry to understand what cell types respond 
to denileukin diftitox treatment and discovered that CD4+ T 
cells were the major cell type in spleen and bone marrow that 
showed activated viruses (Figure 4A and 4B). Other CD4+ cells, 
including plasmacytoid dendritic cells (CD3−CD4+CD123+), 
monocytes/macrophages (CD3−CD4+CD14+), and myeloid 
dendritic cells (CD3−CD14− CD4+CD11c+), did not exhibit 
HIV-1 replication (Figure 4A). Pooled data confirmed the 
preferential activation of HIV-1 gene expression in CD4+ T cells 
induced by Treg depletion (Figure 4B and Supplementary Figure 
6A). We also performed immunofluorescence staining to detect 
both HIV-1–positive myeloid cells (p24+/CD3−) and T cells 
(p24+/CD3+) in spleen. However, all p24+ cells in Treg-depleted, 
cART-recipient mice were CD3+ cells, whereas no significant 
p24 expression was detected in mice that received cART only 
(Figure 4C), indicating that T cells infected with HIV-1 were the 
major reservoir cells responding to Treg depletion. Further anal-
ysis revealed that memory CD4+ T cells (CD3+CD8−CD45RA−) 
but not naive T cells (CD3+CD8−CCR7+CD45RA+) were the 
responding cells in spleen and bone marrow and that both effec-
tor memory CD4+ T cells (CD3+CD8−CCR7−CD45RA−) and 
central memory T cells (CD3+CD8−CCR7+CD45RA−) appeared 
to harbor activated viruses (Figure 5A and 5B). Pooled data 
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Figure 2. Regulatory T-cell (Treg) depletion increases human immunodeficiency virus type 1 (HIV-1) replication in chronically infected humanized mice. Phosphate-buffered 
saline (PBS; mock) or denileukin diftitox (DD; Ontak) was injected 11 weeks after infection to humanized mice infected with HIV-1JRCSF, and all mice were euthanized 2 weeks 
after DD treatment (13 weeks after infection). A, Plasma viral load measured before or after first DD injection. The week −1 time point indicates 1 week before DD treatment. 
B, Representative plots of HIV-1 p24 expression in CD3+CD8− human cells in peripheral blood (PBL), lymph node (LN), and spleen (SP) specimens are shown. C, The frequency 
of p24+ cells in CD3+CD8− cells from PBL, LN, and SP specimens from 3 mice in the mock group, 6 in the HIV-1 group, and 7 in the HIV-1+DD group. D, Immunohistochemical 
staining of HIV-1 p24 (brown) in SP and LN specimens from the mock, HIV-1, and HIV-1+DD groups. The experiments were repeated twice. The data from each experiment 
were merged and summarized. Error bars display standard deviations. *P < .05.
clearly demonstrated the activation of HIV-1 in memory cells in 
vivo (Figure 5C and 5D and Supplementary Figure 6B and 6C). 
Notably, there was no dramatic increase in general immune 
activation in mice that received denileukin diftitox comparing 
to cART alone group (Supplementary Figure 7), as revealed by 
HLA-DR+CD38+ T-cell levels. Therefore, a mechanism other 
than suppression of T-cell activation contributes to suppression 
of HIV-1 replication by Tregs during suppressive cART.
Treg Depletion Leads to a Reduction of HIV-1 Reservoirs In Vivo
Viral replication was resuppressed by cART to an undetectable 
level 13 weeks after infection, and suppression continued until 
15 weeks after infection, which again suggested cART-escape 
mutants or newly infecting viruses were not responsible for the 
rebound in HIV-1 load mediated by Treg depletion (Figure 3A). 
We analyzed the Treg status 12, 13, or 15 weeks after infection 
and found a transient depletion in Tregs at about 1 week after 
denileukin diftitox treatment (Supplementary Figures 4 and 
8). The question is whether this transient activation and sub-
sequent resuppression of viral replication could substantially 
reduce HIV-1 reservoirs. Therefore, we detected cell-associated 
viral DNA and cells with replication-competent virus at either 
13 or 15 weeks after infection. Strikingly, along with the resup-
pression of viral replication, cell-associated viral DNA levels 
were significantly decreased in lymphoid tissue specimens from 
Treg-depleted animals at both 13 and 15 weeks after infection, 
compared with controls (Figure 6A and 6B). Accordingly, cells 
with replication-competent virus were also reduced signifi-
cantly by denileukin diftitox treatment (Figure  6C and 6D). 
However, we did not observe a significant change in both total 
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Figure 3. Regulatory T-cell (Treg) depletion induces human immunodeficiency virus type 1 (HIV-1) reactivation during combination antiretroviral therapy (cART) in humanized 
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euthanized 12 weeks after infection. A, Plasma viral load measured over time. B, Relative levels of cell-associated HIV-1 RNA in human cells from spleen and bone marrow. 
C, Immunohistochemical (IHC) staining of HIV-1 p24 (brown) in spleen specimens from the mock and HIV-1+cART+DD groups. D, Cell-associated HIV-1 DNA copies per million 
human cells in spleen and bone marrow specimens. The experiments were repeated three times. Twelve weeks after infection, data from 2 experiments were combined. Error 
bars display standard deviations. *P < .05.
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Figure 4. Depletion of regulatory T cells (Tregs) reactivates human immunodeficiency virus type 1 (HIV-1) replication in T cells but not in myeloid cells in humanized mice. 
Humanized mice were treated as described in Figure 1A and euthanized 12 weeks after infection. A, Representative histogram shows the percentage of HIVJRCSF gag p24
+ 
cells in CD3+CD8− cells (CD4+ T cells), CD3−CD11c−CD4+CD123+ cells (plasmacytoid dendritic cells [pDCs]), CD3−CD4+CD14+ cells (monocytes/macrophages [mono/mac]), or 
CD3−CD14−CD4+CD11c+ cells (myeloid dendritic cells [mDCs]) in spleen and bone marrow. B, Summarized frequencies of HIVJRCSF gag p24
+ cells in CD4+ T cells, pDCs, mono/
mac, or mDCs in spleen and bone marrow specimens. C, HIVJRCSF p24 in spleen specimens was detected by immunofluorescence staining with anti-human CD3 (green), 
anti-HIV-1 p24 (red), and DAPI (blue). Data are representative results for merged (top) and individual (bottom) stains. Data are pooled from 2 experiments. Error bars display 
standard deviations. cART, combination antiretroviral therapy; DD, denileukin diftitox; HBSS, Hank’s balanced salt solution; PBS, phosphate-buffered saline. *P < .05.
human CD45+ (Supplementary Figure  9) or human CD4+ 
(Supplementary Figure 10) T-cell numbers in spleen and bone 
marrow during 12–15 weeks after infection. Therefore, Treg 
depletion combined with suppressive cART could activate the 
HIV-1 reservoir in memory CD4+ T cells and subsequently re-
duce cART-resistant HIV-1 reservoirs, suggesting that Tregs 
contribute to the persistence of cART-resistant reservoir cells 
in vivo.
HIV-1 Gene Activation in Resting CD4+ T Cells Is Suppressed via Adenylyl 
Cyclase–Dependent cAMP in Tregs
Previous reports suggested that Tregs suppress HIV-1 rep-
lication in conventional T cells through a cAMP-dependent 
mechanism [17, 32–35]. To determine whether cAMP is in-
volved in suppression of HIV-1 activation in conventional T 
cells, we performed experiments on purified CD25− resting 
conventional CD4+ T cells, using the VSV-G HIV-1/eGFP 
reporter virus. Conventional T cells were treated with either 
the cAMP agonist Sp-8-Br-cAMPS (a PKA activator) or H89 
(a PKA inhibitor) 24 hours after reporter virus inoculation 
(Supplementary Figure 11). As demonstrated in Figure 7A and 
7B, HIV-1 gene expression (as determined by GFP expression) 
in conventional T cells was abolished by Sp-8-Br-cAMPS but 
significantly increased in HIV-1-infected cells treated with 
H89. Meanwhile, the GFP mean fluorescence intensity in GFP-
expressing CD4+ T cells was also significantly reduced and 
enhanced, respectively. Notably, we found that a portion of 
HIV-1-infected cells did not express viral genes (ie, as deter-
mined by a lack of GFP expression) in resting cells but could 
be induced to express viral genes by activation with CD3/CD28 
antibody (Supplementary Figure 12). Thus, the increased per-
centage of cells expressing GFP, as well as the mean fluores-
cence intensity of GFP, represents activation or enhancement 
of HIV replication. Furthermore, we treated purified Tregs 
with ddADA (an adenyl cyclase inhibitor) to decrease in-
tracellular levels of cAMP in Tregs, and then we cocultured 
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Figure 5. Regulatory T-cell (Treg) depletion reactivates human immunodeficiency virus type 1 (HIV-1) replication in memory T cells in vivo. Humanized mice were treated 
as described in Figure 1A and euthanized 12 weeks after infection (2 underwent mock infection [mock], 3 underwent HIVJRCSF infection and received phosphate-buffered 
saline [PBS] placebo [JRCSF+PBS], 6 underwent HIVJRCSF infection and received combination antiretroviral therapy [cART] and PBS [JRCSF+cART+PBS], and 6 underwent 
HIVJRCSF infection and received cART and denileukin diftitox [DD; JRCSF+cART+DD]). Naive CD4
+ T cells (TN; CD3
+CD8−CD45RA+CCR7+), central memory CD4+ T cells (TCM; 
CD3+CD8−CD45RA−CCR7+), and effector memory CD4+ T cells (TEM; CD3
+CD8−CD45RA−CCR7−) were analyzed for p24 expression. A and B, Representative histograms of 
HIVJRCSF p24
+ cells in TCM, TEM, and TN in spleen (A) and bone marrow (B) specimens. C and D, Summarized frequencies of HIVJRCSF gag p24
+ cells in TCM, TEM, and TN in spleen 
(C) and bone marrow (D) specimens. Data from 2 experiments are pooled. Error bars display standard deviations. cART, combination antiretroviral therapy; DD, denileukin
diftitox; PBS, phosphate-buffered saline. *P < .05.
them with HIV-1-infected conventional T cells or cocultured 
infected resting CD4+ T cells with Tregs in the presence of the 
cAMP antagonist Rp-8-Br-cAMPS. We found that ddADA sig-
nificantly decreased the suppressive activity of Tregs, whereas 
the cAMP antagonist increased HIV-1 gene expression as com-
pared to the control (Figure 7C and 7D). In parallel, we labeled 
HIV-1–infected resting T cells with BrdU after cAMP agonist 
or PKA inhibitor treatment and detected no difference in cell 
proliferation between treatment and control (Supplementary 
Figure 13). Moreover, no CD25 upregulation was observed in 
cells during an in vitro assay (data not shown). These results 
suggest that Treg-produced cAMP-dependent PKA activation 
plays a pivotal role in Treg-mediated inhibition of HIV-1 acti-
vation or replication in resting CD4+ T cells.
DISCUSSION
Two of the most critical questions in the effort to cure HIV-1 
infection are identification and activation of cART-resistant 
HIV-1–reservoir cells [2]. Humanized mouse models support-
ing a level of HIV DNA persistence in vivo comparable to that in 
HIV patients during suppressive cART [27] have been reported 
to be robust small-animal models for studying HIV-1 infection, 
persistence, and therapy [9, 20, 36–38]. Upon cART cessation, 
HIV-1 rapidly rebounds to pretreatment levels, and the cART-re-
sistant HIV-1 reservoir is associated with latently infected 
memory T cells, as well as with a residual reservoir involving 
low-level replication in lymphoid organs (Figure 1) [29, 30]. We 
demonstrate that depletion of Tregs activates HIV-1 gene expres-
sion or replication in cART-resistant long-lived CD4+ memory T 
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Figure 6. Regulatory T-cell (Treg) depletion combined with suppressive combination antiretroviral therapy (cART) leads to a reduction of human immunodeficiency virus type 
1 (HIV-1) reservoirs in humanized mice. Humanized mice were infected and treated as described in Figure 1A. Mice were euthanized 13 weeks after infection (3 mice under-
went mock infection [mock], 3 underwent HIVJRCSF infection and received phosphate-buffered saline [PBS] placebo [JRCSF+PBS], 5 underwent HIVJRCSF infection and received 
combination antiretroviral therapy [cART] and PBS [JRCSF+cART+PBS], and 6 underwent HIVJRCSF infection and received cART and denileukin diftitox [DD; JRCSF+cART+DD]) 
or 15 weeks after infection (2 in the mock group, 3 in the JRCSF+PBS group, 3 in the JRCSF+cART+PBS group, and 3 in the JRCSF+cART+DD group). A, Cell-associated 
HIVJRCSF DNA copies per million human cells detected by real-time polymerase chain reaction (PCR) in spleen and bone marrow specimens 13 weeks after infection. B, Cell-
associated HIVJRCSF DNA copies per million human cells detected by real-time PCR in spleen and bone marrow specimens 15 weeks after infection. C, Replication-competent 
virus producing cells in spleens detected by the quantitative virus outgrowth assay at 13 weeks after infection. D, Replication-competent HIVJRCSF in spleens detected by the 
quantitative virus outgrowth assay 15 weeks after infection. Data from 2 experiments are combined. Error bars display standard deviations. *P < .05.
cells and subsequently reduces HIV-1 reservoirs during cART in 
vivo (Figures 3–6 and Supplementary Table 1). These findings 
significantly contribute to the understanding of the establish-
ment and persistence of the HIV-1 reservoir in vivo and suggest 
that modulating Treg activity could be a novel strategy to acti-
vate the HIV-1 reservoir and cure infection [39].
A recent study demonstrated that depletion of Tregs in 
simian immunodeficiency virus (SIV)–controlling macaques 
activates latent SIV infection, increases immune activation, and 
boosts the SIV-specific T-cell immune response in the absence 
of cART [40]. It is possible that Treg depletion led to de novo 
SIV infection and increased immune activation, contributing to 
Sp-8-Br-cAMPS
0.08%
(13455)
GFP
DMSOMock
0
0.69%
(24150)
C
D
4
1.06%
(27156)
H89
BA
C
D
0.0
0.2
0.4
0.6
0.8
1.0
G
FP
-e
xp
re
ss
in
g 
ce
lls
 (%
)
*
Tcons
ddADA
Tregs
Rp-8-Br-cAMPS
+ + + +
+ − − −
− − − +
− + + +
− − + −
*
*
HIV-Tcons
0.0
0.5
1.0
1.5
HIV-Tcons − + + +
H89 − − − +
Sp-8-Br-cAMPS − − + −
*
*
G
FP
-e
xp
re
ss
in
g 
ce
lls
 (%
)
HIV-Tcons
Tregs+Rp-8-Br-cAMPS
0.63%
(38974)
Tregs
0.04%
(22614)
TconsMock Tregs+ddADA
0
GFP
C
D
4
0.54%
(25363)
0.35%
(29871)
HIV-Tcons
0
50
100
150
200
HIV-Tcons
Tcons
ddADA
Tregs
Rp-8-Br-cAMPS
R
el
at
iv
e 
vi
ra
l p
ro
du
ct
io
n 
(%
)
+ + + +
+ − − −
− − − +
− + + +
− − + -
*
*
*
Figure 7. Human immunodeficiency virus type 1 (HIV-1) activation and gene expression in CD4+ T cells is suppressed via adenylyl cyclase–dependent cyclic adenosine 
monophosphate (cAMP) in regulatory T cells (Tregs). Resting conventional T cells (Tcons) were inoculated with HIV-1 expressing enhanced green fluorescent protein (GFP) 
and cultured for 24 hours. A and B, The cAMP agonist Sp-8-Br-CAMPS (125 µM), the protein kinase A (PKA) inhibitor H89 (10 µM), and activated Tcons or activated regulatory 
T cells (Tregs) were added into the culture individually. Forty-eight hours later, half of the medium was replaced with fresh medium containing the same amount of each 
compound and cultured for another 48 hours to analyze GFP-expressing CD4+ T cells. A, Representative plots show percentages of GFP-expressing conventional T cells. B, 
Summarized data show percentages of GFP-expressing conventional T cells from panel A. C and D, Coculture of HIV-Tcons with activated Tregs (2:1) with or without pretreat-
ment with 2′,5′-dideoxyadenosine (ddADA) or in the presence of the cAMP antagonist Rp-8-Br-cAMPS. Activated Tcons were used as a control. C, Representative plots show 
percentages of GFP-expressing cells. D, Summarized GFP-expressing cells from Figure 7C are shown in either absolute (left panel) or relative (normalized to HIV-Tcons+Tcons; 
right panel) percentages. Mean fluorescence values for GFP are specified in parentheses in each plot. Bars represent standard deviations. DMSO, dimethyl sulfoxide. *P < .05.
the rebound in virus load, as reported. With suppressive cART 
in this study, the increased cell-associated viral RNA and pro-
tein expression represents virus replication in reservoir cells 
mediated by Treg depletion in vivo, whereas we did not observe 
a marked increase in immune activation when combining Treg 
depletion with cART. More importantly, activation of HIV-1 
reservoirs by treatment with denileukin diftitox reduced lev-
els of HIV-1–reservoir cells in vivo. There are several potential 
mechanisms for the reduction of HIV-1 reservoirs. First, Tregs 
could be HIV-1–reservoir cells themselves, because Tregs are 
susceptible to HIV-1 infection, especially R5 viruses [15, 17], 
and support efficient HIV-1 replication, compared with resting 
conventional CD4+ T cells [32, 33, 41]. Second, Tregs suppress 
immune activation and the anti–HIV-1 immune response, 
which favors HIV-1 persistence [40, 42]. Therefore, Treg deple-
tion could enhance the anti–HIV-1 immune response and kill 
HIV-1–positive cells during the rebound of viral replication. 
Third, CD4+ T cells are sensitive to cytopathic effects induced 
by HIV-1 replication [43]. The mechanisms by which Treg de-
pletion induce significant activation and reduction in the level 
of HIV-1–reservoir cells should be further investigated.
Other reports suggest that proliferation of HIV-1–reservoir 
cells, due to HIV-1 integration in cancer-related genes [44, 45] 
or latency in long-lived memory T stem cells [46], may con-
tribute to HIV-1 reservoir formation and maintenance. A main 
function of Tregs is to suppress naive and memory T-cell activa-
tion and proliferation [47]. Thus, Treg depletion possibly con-
tributes to both the activation of HIV-1 and the expansion of 
HIV-1–reservoir cells. However, our data indicated no signifi-
cant increase in cell-associated viral DNA during the peak level 
of virus rebound after denileukin diftitox treatment. Therefore, 
the increase in HIV replication is unlikely due to the expansion 
of HIV-1–reservoir cells.
The molecular mechanisms by which Tregs suppress HIV-1 ac-
tivation during cART may be multifactorial. Recent reports have 
shown that the CD39/adenosine pathway in Tregs can suppress 
HIV-1 replication in T cells, as well as the activation and function 
of effector T cells [17, 33, 48], which requires cell-cell contact–de-
pendent transfer of cAMP. Using an in vitro system, we showed 
that the suppression of HIV-1 activation and replication in resting 
conventional CD4+ T cells is dependent on PKA activation and 
cAMP produced by Tregs. Further research into the mechanisms 
of Treg-mediated HIV-1 persistence will shed light on the devel-
opment of novel strategies to cure HIV-1 infection.
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